M
Milton Packer
Researcher at Baylor University Medical Center
Publications - 62
Citations - 4200
Milton Packer is an academic researcher from Baylor University Medical Center. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 21, co-authored 62 publications receiving 1745 citations. Previous affiliations of Milton Packer include Imperial College London.
Papers
More filters
Journal ArticleDOI
Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction
Scott D. Solomon,John J.V. McMurray,Inder S. Anand,Junbo Ge,Carolyn S.P. Lam,Aldo P. Maggioni,Felipe Martinez,Milton Packer,Marc A. Pfeffer,Burkert Pieske,Margaret M. Redfield,Jean L. Rouleau,Dirk J. van Veldhuisen,Faiez Zannad,Michael R. Zile,Akshay S. Desai,Brian Claggett,Pardeep S. Jhund,Sergey Boytsov,Josep Comín-Colet,John G.F. Cleland,Hans-Dirk Düngen,Hans-Dirk Düngen,Eva Goncalvesova,Tzvetana Katova,José Francisco Kerr Saraiva,Małgorzata Lelonek,Béla Merkely,Michele Senni,Sanjiv J. Shah,Jingmin Zhou,Adel R. Rizkala,Jianjian Gong,Victor Shi,Martin Lefkowitz +34 more
TL;DR: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failureand an ejection fraction of 45% or higher, and among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit in patients with lower ejection fractions and in women.
Journal ArticleDOI
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan,Brian Claggett,Pardeep S. Jhund,Jonathan W. Cunningham,João Pedro Ferreira,Faiez Zannad,Milton Packer,Milton Packer,Gregg C. Fonarow,John J.V. McMurray,Scott D. Solomon +10 more
TL;DR: The anticipated aggregate treatment effects of early comprehensive disease-modifying pharmacological therapy are substantial and support the combination use of an ARNI, β blocker, MRA, and SGLT2 inhibitor as a new therapeutic standard among patients with chronic HFrEF.
Journal ArticleDOI
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D. Solomon,Muthiah Vaduganathan,Brian Claggett,Milton Packer,Milton Packer,Michael R. Zile,Michael R. Zile,Karl Swedberg,Karl Swedberg,Jean L. Rouleau,Marc A. Pfeffer,Akshay S. Desai,Lars Lund,Lars Køber,Inder S. Anand,Nancy K. Sweitzer,Gerard C.M. Linssen,Béla Merkely,Juan Luis Arango,Dragos Vinereanu,Chen Huan Chen,Michele Senni,Antonio S. Sibulo,Sergey Boytsov,Victor Shi,Adel R. Rizkala,Martin Lefkowitz,John J.V. McMurray +27 more
TL;DR: The therapeutic effects of sacubitril/valsartan, compared with a renin-angiotensin-aldosterone–system inhibitor alone, vary by LVEF with treatment benefits, particularly for heart failure hospitalization, that appear to extend to patients with heart failure and mildly reduced ejection fraction.
Journal ArticleDOI
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Stefan D. Anker,Javed Butler,Gerasimos Filippatos,Muhammad Shahzeb Khan,Nikolaus Marx,Carolyn S.P. Lam,Sven Schnaidt,Anne Pernille Ofstad,Martina Brueckmann,Martina Brueckmann,Martina Brueckmann,Waheed Jamal,Edimar Alcides Bocchi,Piotr Ponikowski,Sergio V. Perrone,James L. Januzzi,Subodh Verma,Michael Böhm,Michael Böhm,Michael Böhm,João Pedro Ferreira,Stuart J. Pocock,Faiez Zannad,Milton Packer,Milton Packer +24 more
TL;DR: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empaglif Lozin significantly improved cardiovascular and renal outcomes in patients with heart failure and a reduced ejection fraction, independent of baseline diabetes status and across the continuum of HbA1c.
Journal ArticleDOI
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Milton Packer,Milton Packer,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,João Pedro Ferreira,Stuart J. Pocock,Peter E. Carson,Inder S. Anand,Wolfram Doehner,Markus Haass,Michel Komajda,Alan B. Miller,S. Pehrson,John R. Teerlink,Martina Brueckmann,Waheed Jamal,Cordula Zeller,Sven Schnaidt,Faiez Zannad +19 more
TL;DR: In patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy.